Top Tweets for #antiegfr
Thank you @ClinAdv and @GIcancerDoc for inviting me to discuss the topic of #antiEGFR retreatment/rechallenge in #mCRC #crcsm
https://t.co/DGITAh5lzO
CRC In Focus, Clinical Advances in Hematology & Oncology
@CSCancerCenter @OncoAlert
“EGFR Inhibitor Rechallenge in Metastatic Colorectal Cancer” with Jun Gong, MD https://t.co/OR9GbI1Urn @jgong15
Impact of #AntiEGFR Therapies on #HER2-Positive Metastatic #Colorectalcancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes https://t.co/oVAM9rgo3j
Very interesting paper by Adithya Chennamadhavuni and @pashtoonkasi #antiegfr #rechallenge #mcrc #precisionmedicine Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge https://t.co/eohal0dSjR
"Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer"
Author(s): Sankha Bhattacharya*
Check it out here ➡️ https://t.co/2v3mP4Baea
#AntiEGFR #5Fluorouracil #nanoparticles
#IMPROVEstudy #ASCO22
👇 Intermittent vs continuous FOLFIRI/PANI #antiegfr
🔸PFSot: 17.1 vs 13.2 mo
🔹Left sided PFSot: 20.2 vs 13.2 mo
🔺➖ severe skin toxicity
@OncoAlert #CRCSM
📢 GI staff @istitutotumori waiting for
#IMPROVEstudy #ASCO22 abs.3503
👇
Intermittent vs continuous FOLFIRI/PANITUMUMAB as 1line for pts with RAS/BRAF wt mCRC
❓#stopandgo for #antiEGFR: yes or no? Can't wait for the #OralAbstractSession #mCRC
📢 #IMPROVEstudy is on stage at #ASCO22 abs.3503
👇
Intermittent vs continuous FOLFIRI/PANITUMUMAB as 1line for pts with RAS/BRAF wt mCRC
❓#stopandgo for #antiEGFR: yes or no? Can't wait for the #OralAbstractSession #mCRC @istitutotumori
⏰6 jun 2022 | 16:45 – 19:45 CEST
🚨HOY 1️⃣8️⃣ MAYO 🚨
II SIMPOSIO MEDICINA DE PRECISIÓN EN CABEZA Y CUELLO #HN #SCCHN
🚨BIOMARCADORES 🚨
#AntiEGFR #Cetuximab
Magnifica ponencia a cargo de la Dra. Almudena García Castaño del Hospital Marqués de Valdecilla en Santander 👇
🚨ONCO-ID🚨
NO TE LO PIERDAS!!!
25/11/20 15:30 CET: #SCCHN🔬🩸🧬🧪
- #AntiEGFR
- #Inmunoterapia #IO
- #BiopsiaLiquida
-#Microbioma
-#Cirugia
-#Radioterapia
Dra. M Iglesias
@perezsegura2
Dra. I Braña
@OlivaM_Onc
Dra. V García
@ManuelGmezSerr1
Dr. J Giralt
@SantiCabezas1
🚨PROGRAMA ONCO-ID 2️⃣4️⃣➖2️⃣6️⃣ NOV 2020🚨
25/11/20: #SCCHN🔬🩸🧬🧪
- #AntiEGFR
- #Inmunoterapia #IO
- #BiopsiaLiquida
-#Microbioma
-#Cirugia
-#Radioterapia
Dra. M Iglesias
@perezsegura2
Dra. I Braña
@OlivaM_Onc
Dra. V García
@ManuelGmezSerr1
Dr. J Giralt
@SantiCabezas1
PhD studentship opportunity @LabSadanandam @ICR_London in collaboration with @merckgroup in #colon cancer #crc and #antiegfr #therapy resistance
#PhD #PhDposition #phdstudent
#studentship #Career
https://t.co/QpVMHaBoHd
Analysis of #heterogeneity within #colorectalcancer patients treated #antiEGFR showed transit-amplifying signature is associated #prognosis tumour #sidedness CO.20 trial @LabSadanandam @ElisaFontana83 @ICR_London @royalmarsdenNHS @CDNCancerTrials
https://t.co/uYfo0XD0X2
#crcsm
⚡️Just OUT @ElsevierConnect
#AXL is a predictor of poor survival and of resistance to #antiEGFR therapy in patients with RAS wild-type metastatic colorectal cancer #CRCSM
So proud to share this👇
https://t.co/MOEYtTcKsq
#TeamWork is the key in #CancerResearch
@LabSadanandam @ICR_London Elisa's poster was discussed at #ESMO2019. This is our positive #biomarker-based on transit amplifying CRCAssigner subtype for #antiEGFR therapy in #colorectalcancer
Undergoing studies as #PERSEIDA will elucidate #liquidbiopsy role in clinical utility. Setting #MAF cut-off will consolidate its use in #CRC #antiEGFR treatment resistance, response and #retreatment
#precisionmedicine #BEAMing #RevCáncer2019 #revisionesencáncer @SysmexInostics
First results of fully enrolled phase II trial combining #monalizumab and #cetuximab, respectively #antiNKG2A and #antiEGFR, on recurrent or #metastatic #SCCHN. See our poster at #AACR18 https://t.co/iKTsI0YUgz
Toxicidad Cutánea asociada a #antiEGFR #ToxicidadxQT ➕info en https://t.co/pnLObvNP8E…
Abro hilo 👇🏼 https://t.co/6Y4V9cEq6j
Hoy #ToxicidadxQT #antiEGFR Tox.Cutánea RASH en zonas ricas en glándulas sebáceas
Fases RASH
F1: Alterac.Sensitiva +Eritema+Edema (sem 0-1)
F2: Papulopustular (sem 1-3)
F3: Costra (sem 3-5)
F4: Eritemato-telangiectasia
Ciclo 2 Panitum.+Oxaliplatino
Ej Rash Fase 3 👇🏼
Hoy #ToxicidadxQT #antiEGFR Tox.Cutánea RASH en zonas ricas en glándulas sebáceas
Fases RASH
F1: Alterac.Sensitiva +Eritema+Edema (sem 0-1)
F2: Papulopustular (sem 1-3)
F3: Costra (sem 3-5)
F4: Eritemato-telangiectasia
Ciclo 2 Panitum.+Oxaliplatino
Ej Rash Fase 3 👇🏼
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.8M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers